Pharma export council to open offices abroad

Image
P B Jayakumar Mumbai
Last Updated : Jan 21 2013 | 2:54 AM IST

The Pharmaceutical Exports Promotion Council (Pharmexcil) will soon start offices and warehouses in the US, Europe, Latin America and Japan to help Indian drug exporters boost their business in markets abroad.

Pharmexcil, under the Ministry of Commerce, is working out a detailed strategy paper in this regard, said Smitesh Shah, chairman.

“These four markets constitute a majority of exports by our members (over 1,500) and the move is to help in market development and to bring down export costs by using common warehousing facilities and office infrastructure, especially for companies entering into newer geographies,” he said.

Six-year-old Pharmexcil has regional offices in Mumbai, New Delhi and Ahmedabad, besides headquarters in Hyderabad.

Shah said though pharmaceutical exports were down in the April to October period of 2009, recent trends showed these had picked up. A temporary slowing was mainly due to the global slowdown in 2008-09 period, which resulted in less orders from overseas wholesalers to clear their inventories and less than expected orders from multinational companies for contract manufacturing.

The growth in drug exports from India decreased to about 10-12 per cent in the first three quarters of 2009-10, in comparison to Rs 39,537.7 crore of exports, with a 29 per cent growth, recorded in 2008-09, showed data from the Directorate General of Commercial Intelligence & Statistics (DGCI&S) and the Centre for Monitoring Indian Economy (CMIE). India’s drug exports grew at an average rate of 21 per cent in the past four years.

Shah said India’s drug exports were likely to show above 15 per cent growth for 2009-10. India’s $12-billion (Rs 53,500 crore) pharmaceutical industry earns 40 per cent of its revenue from exports of off-patent generic drugs.

A CII-KPMG report estimates total Indian pharma output (including that for export markets) would be growing at a compounded annual rate of 16 per cent over 2007-11. According to a Mckinsey report, the domestic pharmaceutical market is set to grow from $6.3 billion (Rs 28,000 crore) in 2005 to $20 billion (Rs 89,000 crore) by 2015, with a growth rate of 12.3 per cent.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 15 2010 | 12:55 AM IST

Next Story